Literature DB >> 2664509

Final report on the aspirin component of the ongoing Physicians' Health Study.

.   

Abstract

The Physicians' Health Study is a randomized, double-blind, placebo-controlled trial designed to determine whether low-dose aspirin (325 mg every other day) decreases cardiovascular mortality and whether beta carotene reduces the incidence of cancer. The aspirin component was terminated earlier than scheduled, and the preliminary findings were published. We now present detailed analyses of the cardiovascular component for 22,071 participants, at an average follow-up time of 60.2 months. There was a 44 percent reduction in the risk of myocardial infarction (relative risk, 0.56; 95 percent confidence interval, 0.45 to 0.70; P less than 0.00001) in the aspirin group (254.8 per 100,000 per year as compared with 439.7 in the placebo group). A slightly increased risk of stroke among those taking aspirin was not statistically significant; this trend was observed primarily in the subgroup with hemorrhagic stroke (relative risk, 2.14; 95 percent confidence interval, 0.96 to 4.77; P = 0.06). No reduction in mortality from all cardiovascular causes was associated with aspirin (relative risk, 0.96; 95 percent confidence interval, 0.60 to 1.54). Further analyses showed that the reduction in the risk of myocardial infarction was apparent only among those who were 50 years of age and older. The benefit was present at all levels of cholesterol, but appeared greatest at low levels. The relative risk of ulcer in the aspirin group was 1.22 (169 in the aspirin group as compared with 138 in the placebo group; 95 percent confidence interval, 0.98 to 1.53; P = 0.08), and the relative risk of requiring a blood transfusion was 1.71. This trial of aspirin for the primary prevention of cardiovascular disease demonstrates a conclusive reduction in the risk of myocardial infarction, but the evidence concerning stroke and total cardiovascular deaths remains inconclusive because of the inadequate numbers of physicians with these end points.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2664509     DOI: 10.1056/NEJM198907203210301

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  553 in total

Review 1.  Advances in the medical management of acute coronary syndromes.

Authors:  C P Cannon
Journal:  J Thromb Thrombolysis       Date:  1999-04       Impact factor: 2.300

2.  Authors' reply on aspirin for primary prevention.

Authors:  T W Meade ; P J Brennan
Journal:  BMJ       Date:  2001-01-20

Review 3.  Randomised controlled trials in cardiovascular medicine: past achievements, future challenges.

Authors:  S Yusuf
Journal:  BMJ       Date:  1999-08-28

Review 4.  Platelet PlA2 polymorphism and thromboembolic events: from inherited risk to pharmacogenetics.

Authors:  P J Goldschmidt-Clermont; C M Roos; G E Cooke
Journal:  J Thromb Thrombolysis       Date:  1999-08       Impact factor: 2.300

5.  Clotting for the Clinician: An Overview of Thrombosis and Antithrombotic Therapy.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

6.  Aspirin for primary prevention. Treatment policy should be based on all trial evidence, not subgroup analysis.

Authors:  L E Ramsay; P S Sanmuganathan; E J Wallis; P R Jackson
Journal:  BMJ       Date:  2000-12-09

7.  Aspirin, like all other drugs, is a poison.

Authors:  M R Tramèr
Journal:  BMJ       Date:  2000-11-11

8.  Chronic aspirin is effective--if data are massaged sufficiently.

Authors:  John G F Cleland
Journal:  BMJ       Date:  2002-02-02

9.  Body mass index and the incidence of visually significant age-related maculopathy in men.

Authors:  D A Schaumberg; W G Christen; S E Hankinson; R J Glynn
Journal:  Arch Ophthalmol       Date:  2001-09

Review 10.  Management of diabetic nephropathy.

Authors:  L Foggensteiner; S Mulroy; J Firth
Journal:  J R Soc Med       Date:  2001-05       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.